173 related articles for article (PubMed ID: 10858346)
1. Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts.
Arany I; Tyring SK; Brysk MM; Stanley MA; Tomai MA; Miller RL; Smith MH; McDermott DJ; Slade HB
Antimicrob Agents Chemother; 2000 Jul; 44(7):1869-73. PubMed ID: 10858346
[TBL] [Abstract][Full Text] [Related]
2. The immune response modifier imiquimod requires STAT-1 for induction of interferon, interferon-stimulated genes, and interleukin-6.
Bottrel RL; Yang YL; Levy DE; Tomai M; Reis LF
Antimicrob Agents Chemother; 1999 Apr; 43(4):856-61. PubMed ID: 10103191
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%.
Arany I; Tyring SK; Stanley MA; Tomai MA; Miller RL; Smith MH; McDermott DJ; Slade HB
Antiviral Res; 1999 Aug; 43(1):55-63. PubMed ID: 10480263
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod.
Tyring SK; Arany I; Stanley MA; Tomai MA; Miller RL; Smith MH; McDermott DJ; Slade HB
J Infect Dis; 1998 Aug; 178(2):551-5. PubMed ID: 9697742
[TBL] [Abstract][Full Text] [Related]
5. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M
Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
[TBL] [Abstract][Full Text] [Related]
6. Warts treatment.
Treat Rev; 1995 Nov; (no 20):7. PubMed ID: 11363030
[TBL] [Abstract][Full Text] [Related]
7. Treatment of genital warts with an immune-response modifier (imiquimod).
Beutner KR; Spruance SL; Hougham AJ; Fox TL; Owens ML; Douglas JM
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):230-9. PubMed ID: 9486679
[TBL] [Abstract][Full Text] [Related]
8. Imiquimod: an immune response modifier.
Dahl MV
J Am Acad Dermatol; 2000 Jul; 43(1 Pt 2):S1-5. PubMed ID: 10861100
[No Abstract] [Full Text] [Related]
9. Cytokine induction and modifying the immune response to human papilloma virus with imiquimod.
Slade HB
Eur J Dermatol; 1998; 8(7 Suppl):13-6; discussion 20-2. PubMed ID: 10387958
[TBL] [Abstract][Full Text] [Related]
10. [Imiquimod: immunologic-response modifier].
Berman B
Ann Dermatol Venereol; 2000; 127(10 Suppl):3S15-3S18. PubMed ID: 11116858
[No Abstract] [Full Text] [Related]
11. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations.
Sauder DN; Skinner RB; Fox TL; Owens ML
Sex Transm Dis; 2003 Feb; 30(2):124-8. PubMed ID: 12567169
[TBL] [Abstract][Full Text] [Related]
12. Identification and partial characterization of FRAG-6, a novel interferon-stimulated gene that is expressed in an IRF-1-INDEPENDENT manner.
Silva AM; Bottrel RL; Reis LF
Cytokine; 1999 Nov; 11(11):813-21. PubMed ID: 10547268
[TBL] [Abstract][Full Text] [Related]
13. [Mechanisms of imiquimod indirect antiviral activity].
Hober D; Ajram L; Chehadeh W; Lazrek M; Goffard A; Dewilde A; Wattré P
Ann Biol Clin (Paris); 2005; 63(2):155-63. PubMed ID: 15771973
[TBL] [Abstract][Full Text] [Related]
14. Topical imiquimod: a review of its use in genital warts.
Perry CM; Lamb HM
Drugs; 1999 Aug; 58(2):375-90. PubMed ID: 10473026
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts.
Beutner KR; Tyring SK; Trofatter KF; Douglas JM; Spruance S; Owens ML; Fox TL; Hougham AJ; Schmitt KA
Antimicrob Agents Chemother; 1998 Apr; 42(4):789-94. PubMed ID: 9559784
[TBL] [Abstract][Full Text] [Related]
16. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day.
Fife KH; Ferenczy A; Douglas JM; Brown DR; Smith M; Owens ML;
Sex Transm Dis; 2001 Apr; 28(4):226-31. PubMed ID: 11318254
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod for the treatment of genital warts: a quantitative systematic review.
Moore RA; Edwards JE; Hopwood J; Hicks D
BMC Infect Dis; 2001; 1():3. PubMed ID: 11401728
[TBL] [Abstract][Full Text] [Related]
18. Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck.
Arany I; Chen SH; Megyesi JK; Adler-Storthz K; Chen Z; Rajaraman S; Ember IA; Tyring SK; Brysk MM
Cancer Lett; 2003 Sep; 199(1):83-9. PubMed ID: 12963127
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation.
Cassatella MA; Gasperini S; Bovolenta C; Calzetti F; Vollebregt M; Scapini P; Marchi M; Suzuki R; Suzuki A; Yoshimura A
Blood; 1999 Oct; 94(8):2880-9. PubMed ID: 10515892
[TBL] [Abstract][Full Text] [Related]
20. Activation of the Stat3 signaling pathway is required for differentiation by interleukin-6 in PC12-E2 cells.
Wu YY; Bradshaw RA
J Biol Chem; 2000 Jan; 275(3):2147-56. PubMed ID: 10636920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
